Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Clinical trial NCT04502030 · COMPLETED
Trial details
- NCT number
- NCT04502030
- Sponsor
- Octapharma
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-05
- Primary completion
- 2025-09-19
- Enrollment
- 247
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.